Search Results
Search for other papers by Salma Ben-Salem in
Google Scholar
PubMed
Search for other papers by Varadha Balaji Venkadakrishnan in
Google Scholar
PubMed
Search for other papers by Hannelore V Heemers in
Google Scholar
PubMed
Introduction Prostate cancer (CaP) remains the second leading cause of cancer deaths in Western men ( Siegel et al. 2020 ). These deaths occur because of acquired resistance to the systemic therapies for metastatic CaP. Because of CaP
Search for other papers by Kristina V Wells in
Google Scholar
PubMed
Search for other papers by Margaret L Krackeler in
Google Scholar
PubMed
Veterans Affairs-Northern California Health System, Mather, California, USA
Search for other papers by Maitreyee K Jathal in
Google Scholar
PubMed
Search for other papers by Mamta Parikh in
Google Scholar
PubMed
Department of Urologic Surgery, School of Medicine, University of California Davis, Sacramento, California, USA
Search for other papers by Paramita M Ghosh in
Google Scholar
PubMed
Department of Biomedical Engineering, University of California Davis, Davis, California, USA
Search for other papers by J Kent Leach in
Google Scholar
PubMed
Search for other papers by Damian C Genetos in
Google Scholar
PubMed
Introduction Prostate cancer (PCa) is a highly prevalent health problem in the developed world. As an age-related disease that is exacerbated by Western diets and lifestyles, the global burden of PCa will only continue to rise as lifespans
Search for other papers by Fritz H Schröder in
Google Scholar
PubMed
Introduction Endocrine treatment (ET) of prostate cancer (PC) is more than 60 years old ( Huggins & Hodges 1941 , Huggins et al. 1941 ). Huggins and coworkers were awarded the Nobel Prize in 1966 for their studies in endocrine
Search for other papers by Rana P Singh in
Google Scholar
PubMed
Search for other papers by Rajesh Agarwal in
Google Scholar
PubMed
Introduction Prostate cancer (PCa) is a chronic disease, and therefore, its chemoprevention is emerging as an attractive additional strategy for disease control. In recent years, considerable progress has been made in this direction
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Benjamin C Thomas in
Google Scholar
PubMed
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Molecular Diagnostics and Therapeutics Group, University College London, London, UK
Search for other papers by Jonathan D Kay in
Google Scholar
PubMed
Astra Zeneca, 2 Riverside, Granta Park, Cambridge, UK
Search for other papers by Suraj Menon in
Google Scholar
PubMed
Astra Zeneca, 2 Riverside, Granta Park, Cambridge, UK
Search for other papers by Sarah L Vowler in
Google Scholar
PubMed
Search for other papers by Sarah N Dawson in
Google Scholar
PubMed
Search for other papers by Laura J Bucklow in
Google Scholar
PubMed
Molecular Diagnostics and Therapeutics Group, University College London, London, UK
Search for other papers by Hayley J Luxton in
Google Scholar
PubMed
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Thomas Johnston in
Google Scholar
PubMed
Molecular and Computational Diagnostics Group, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Search for other papers by Charlie E Massie in
Google Scholar
PubMed
Search for other papers by Michelle Pugh in
Google Scholar
PubMed
Search for other papers by Anne Y Warren in
Google Scholar
PubMed
Search for other papers by Peter Barker in
Google Scholar
PubMed
Search for other papers by Keith Burling in
Google Scholar
PubMed
Search for other papers by Andy G Lynch in
Google Scholar
PubMed
Search for other papers by Anne George in
Google Scholar
PubMed
Search for other papers by Johanna Burge in
Google Scholar
PubMed
Search for other papers by Marie Corcoran in
Google Scholar
PubMed
Search for other papers by Sara Stearn in
Google Scholar
PubMed
Search for other papers by Alastair D Lamb in
Google Scholar
PubMed
Search for other papers by Naomi L Sharma in
Google Scholar
PubMed
University College Hospital at Westmoreland Street, London, UK
Search for other papers by Greg L Shaw in
Google Scholar
PubMed
Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Headington, Oxford, UK
Search for other papers by David E Neal in
Google Scholar
PubMed
Biomarker Initiative, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK
Molecular Diagnostics and Therapeutics Group, University College London, London, UK
Search for other papers by Hayley C Whitaker in
Google Scholar
PubMed
Introduction Prostate cancer is the leading cause of cancer death in men ( Office for National Statistics 2013 ). Prostate cancer growth relies upon androgens, such as testosterone, binding to the androgen receptor (AR) and promoting AR
Search for other papers by Karin Jennbacken in
Google Scholar
PubMed
Search for other papers by Tajana Tešan in
Google Scholar
PubMed
Search for other papers by Wanzhong Wang in
Google Scholar
PubMed
Search for other papers by Heléne Gustavsson in
Google Scholar
PubMed
Search for other papers by Jan-Erik Damber in
Google Scholar
PubMed
Search for other papers by Karin Welén in
Google Scholar
PubMed
importance for metastasis of prostate cancer ( Xie et al . 2010 ). In contrast to N-cadherin, E-cadherin mediates homotypic interactions between cells, which maintain the integrity of epithelial tissues ( Giehl & Menke 2008 ). Functional studies show that N
Search for other papers by S Darby in
Google Scholar
PubMed
Search for other papers by J Stockley in
Google Scholar
PubMed
Search for other papers by M M Khan in
Google Scholar
PubMed
Search for other papers by C N Robson in
Google Scholar
PubMed
Search for other papers by H Y Leung in
Google Scholar
PubMed
Search for other papers by V J Gnanapragasam in
Google Scholar
PubMed
Introduction Prostate cancer remains the most commonly diagnosed malignancy and the second leading cause of cancer-related deaths among men in the USA ( Jemal et al. 2006 ). Gonadotrophin-releasing hormone I (GnRH I) analogue
Search for other papers by Vijay K Gonugunta in
Google Scholar
PubMed
Search for other papers by Lu Miao in
Google Scholar
PubMed
Department of Obstetrics and Gynecology UT Health Science Center, San Antonio, Texas, USA
Search for other papers by Gangadhara R Sareddy in
Google Scholar
PubMed
Search for other papers by Preethi Ravindranathan in
Google Scholar
PubMed
Department of Obstetrics and Gynecology UT Health Science Center, San Antonio, Texas, USA
Search for other papers by Ratna Vadlamudi in
Google Scholar
PubMed
Search for other papers by Ganesh V Raj in
Google Scholar
PubMed
2007 , Girard et al . 2013 ). This review focuses on the structure, function, and genomic and extranuclear signaling of PELP1, associated signaling pathways, and its role as a target for therapeutic modulation in breast and prostate cancers. PELP1
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Search for other papers by Parvin Yenki in
Google Scholar
PubMed
Search for other papers by Satyam Bhasin in
Google Scholar
PubMed
Search for other papers by Liang Liu in
Google Scholar
PubMed
Search for other papers by Noushin Nabavi in
Google Scholar
PubMed
Search for other papers by Chi Wing Cheng in
Google Scholar
PubMed
Search for other papers by Kevin J Tam in
Google Scholar
PubMed
Search for other papers by James W Peacock in
Google Scholar
PubMed
Search for other papers by Hans H Adomat in
Google Scholar
PubMed
Search for other papers by Tabitha Tombe in
Google Scholar
PubMed
Search for other papers by Ladan Fazli in
Google Scholar
PubMed
Search for other papers by Larissa Ivanova in
Google Scholar
PubMed
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Search for other papers by Christopher Dusek in
Google Scholar
PubMed
Search for other papers by Shahram Khosravi in
Google Scholar
PubMed
Search for other papers by Emma S Tomlinson Guns in
Google Scholar
PubMed
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Search for other papers by Yuzhuo Wang in
Google Scholar
PubMed
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Search for other papers by Ralph Buttyan in
Google Scholar
PubMed
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Search for other papers by Martin E Gleave in
Google Scholar
PubMed
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Search for other papers by Christopher J Ong in
Google Scholar
PubMed
Introduction Despite its initial efficacy, androgen deprivation therapy (ADT) remains a palliative treatment for metastatic prostate cancer, and patients eventually progress to castration-resistant prostate cancer (CRPC) ( So et al. 2005
Search for other papers by Penelope D Ottewell in
Google Scholar
PubMed
Search for other papers by Ning Wang in
Google Scholar
PubMed
Search for other papers by Joshua Meek in
Google Scholar
PubMed
Search for other papers by C Anne Fowles in
Google Scholar
PubMed
Search for other papers by Peter I Croucher in
Google Scholar
PubMed
Search for other papers by Colby L Eaton in
Google Scholar
PubMed
Search for other papers by Ingunn Holen in
Google Scholar
PubMed
Introduction Prostate cancer is the most common malignancy and the second most common cause of cancer death in men. In the USA, there were ∼238 590 new prostate cancer diagnoses and more than 29 720 deaths in 2013 ( American Society for Cancer 2013